Dermata Therapeutics
DRMA
10 hedge funds and large institutions have $140K invested in Dermata Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
67% more funds holding
Funds holding: 6 → 10 (+4)
54% more capital invested
Capital invested by funds: $91K → $140K (+$49.4K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$546K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$68K |
| 3 |
Citigroup
New York
|
+$41.2K |
| 4 |
SCA
Sage Capital Advisors
Sioux Falls,
South Dakota
|
+$10.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$22K |
| 2 |
JP Morgan Chase
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $52K | +$68K | +33 | New |
|
|
2
Citigroup
New York
| $32K | +$41.2K | +20 | New |
|
3
Geode Capital Management
Boston,
Massachusetts
| $17K | – | – | – |
|
|
SCA
4
Sage Capital Advisors
Sioux Falls,
South Dakota
| $8K | +$10.3K | +5 | New |
|
5
Tudor Investment Corp
Stamford,
Connecticut
| $7K | – | – | – |
|
6
Wells Fargo
San Francisco,
California
| $7K | – | – | – |
|
7
UBS Group
Zurich,
Switzerland
| $7K | +$6.18K | +3 | +150% |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $7K | +$10.3K | +5 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $3K | +$2.06K | +1 | +100% |
|
|
AC
10
Armistice Capital
New York
| $414 | +$546K | +265 | New |
|
|
11
BlackRock
New York
| – | -$22K | -7 | Closed |
|
|
12
JP Morgan Chase
New York
| – | -$1K | – | – |
|
DRMA Hedge Fund Activity: Q2 2022 in Review
10 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q2 2022, worth a combined $140K — up 54% from $91K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DRMA positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $546K. The largest seller was BlackRock, exiting entirely with an estimated $22K sold.
- 10 institutional investors held Dermata Therapeutics (DRMA) as of Q2 2022, up from 6 in Q1 2022.
- Funds reported $140K of Dermata Therapeutics stock for Q2 2022, up 54% quarter-over-quarter.
- 5 funds opened new Dermata Therapeutics positions in Q2 2022 and 1 closed out, a net change of +4 holders.
- The largest Dermata Therapeutics buyer in Q2 2022 was Armistice Capital, an estimated $546K added.
- The largest Dermata Therapeutics seller in Q2 2022 was BlackRock, an estimated $22K sold.
Based on aggregated 13F filings for Q2 2022.